WGS GeneDx Holdings Corp. Debts to Book Capitalization

GeneDx Corp (WGS) - corporate logo

GeneDx Holdings Corp. (WGS) is minimizing operational losses by focusing on high-margin sequencing, although it remains dependent on insurance reimbursement conditions. Monetization is based on the sale of Big Data licenses, where the asset value reflected in the pakistan chart is 0.72. Under the leadership of Jessica Dumichell, the business is implementing AI solutions for genome analysis, aiming to become a key tool in medical diagnostics.

WGS GeneDx Corp: Debt to Book Value Ratio in the range 04/28/2023 - 10/29/2026
Product sample of GeneDx Corp

This ratio determines the issuer's solvency by comparing total credit obligations to the market value of equity to assess default risk and the efficiency of leverage. In the context of GeneDx Holdings Corp. (WGS) expanding through the acquisition of AI platforms and strategic alliances, the proportion of debt within the firm's balance sheet capitalization reflects the balance between the aggressive development of genomic diagnostics and the financial stability of its assets.

Key competitors

Debts to Book Capitalization TEM (Tempus AI Inc)|Debt to Net Assets qiagen.com|Ionis - Debts to Book Capitalization|Debts to Book Value Repligen Corp|Avidity (RNA) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio CRSP|RARE (Ultragenyx Pharmaceutical) - Debts to Book Capitalization|Debts to Book Value beamtx.com BEAM|Debts to Book Capitalization SRPT|Twist Bioscience Inc - Debt to Book Value Ratio|10x Genomics Corp - Debt to Book Value|NTLA: Debt to Book Value Ratio|STOK: Debt to Book Value|Debt to Net Assets Ratio BLFS (biolifesolutions.com)|WVE: Debts to Book Capitalization|Maze Therapeutics, Inc. - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Sionna Pharma|Debts to Book Value Prime Medicine Bio PRME|Debt to Book Capitalization Ratio Taysha Gene Therapies (TSHA)|Debt to Book Capitalization Ratio QURE (uniqure.com)|Debts to Book Capitalization MGTX (MeiraGTx)|RGNX: Debt to Book Value Ratio|Solid Bio - Debts to Book Capitalization|Debts to Net Assets Ocugen Pharma OCGN|Pacific Biosciences (PACB) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio BNTC|DSGN (Design Therapeutics, Inc.) - Debts to Book Capitalization|RCKT - Debt to Net Assets|Debt to Book Capitalization Ratio 4D Molecular Therapeutics Inc (FDMT)|Debts to Net Assets lexeotx.com|Korro Bio - Debt to Book Value|Debt to Net Assets Ratio EDIT|Silence Therapeutics plc - Debts to Book Capitalization|ProQR Therapeutics N.V. (PRQR) - Debt to Book Value|codexis.com (CDXS) - Debt to Book Capitalization Ratio|Debts to Book Value Sangamo BioSciences (SGMO)|Debt to Book Capitalization Ratio Nautilus Biotechnology, Inc.|MGX: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Precision BioSciences, Inc. (DTIL)|GBIO: Debts to Book Capitalization Ratio|Boundless Bio, Inc - Debt to Book Value|Debts to Net Assets Exicure Inc. (XCUR)|IMNN: Debt to Book Value|Phio Pharmaceuticals (PHIO) - Debt to Book Value|MBIO: Debts to Book Capitalization|Debt to Net Assets TransCode Therapeutics, Inc. RNAZ|Debt to Book Capitalization Ratio Bionano Genomics Inc.|Applied DNA Corp (APDN) - Debts to Net Assets|Debts to Book Capitalization BLUE|immunoprecise.com - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Omega Therapeutics, Inc. OMGA|OMIC: Debt to Book Value Ratio|Regulus Therapeutics Inc - Debts to Book Capitalization|SYRS - Debts to Book Capitalization|TBIO: Debts to Book Capitalization|Debt to Net Assets traconpharma.com TCON|UBX (Unity Biotechnology, Inc.) - Debts to Book Capitalization